Quick Answer
AXIM BIOTECHNOLOGIES, INC. reported Operating Income Loss of -$2.75 million for the year ending 2023.
- AXIM BIOTECHNOLOGIES, INC. showed an increase of +40.9% in Operating Income Loss from 2022 to 2023.
- This data is from AXIM BIOTECHNOLOGIES, INC.'s annual report (Form 10-K), filed with the SEC on April 16, 2024.
- XBRL data for this metric is available from 2016 to 2023 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2014: -$127.9 thousand | Q3 2015: -$1.69 million | Q1 2016: -$942.2 thousand | Q2 2016: -$491.5 thousand | Q3 2016: -$1.56 million | Q1 2017: -$476.3 thousand | Q2 2017: -$437.2 thousand | Q3 2017: -$1.19 million | Q1 2018: -$2.04 million | Q2 2018: -$1.34 million | Q3 2018: -$935.8 thousand | Q1 2019: -$2.29 million | Q2 2019: -$1.84 million | Q3 2019: -$1.11 million | Q2 2020: -$662.9 thousand | Q3 2020: -$1.30 million | Q1 2021: -$868.0 thousand | Q2 2021: -$2.18 million | Q3 2021: -$3.28 million | Q1 2022: -$1.13 million | Q2 2022: -$1.06 million | Q3 2022: -$1.32 million | Q1 2023: -$710.6 thousand | Q2 2023: -$697.7 thousand | Q3 2023: -$588.5 thousand | Q1 2024: -$404.4 thousand | Q2 2024: -$569.4 thousand.
- Over the full 6 years of available data (2016 to 2023), AXIM BIOTECHNOLOGIES, INC.'s Operating Income Loss has grown by 26.8%.
- Historical annual values: Fiscal year 2023: -$2.75 million | Fiscal year 2022: -$4.65 million | Fiscal year 2021: -$13.97 million | Fiscal year 2018: -$5.04 million | Fiscal year 2017: -$3.15 million | Fiscal year 2016: -$3.76 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: